Home>>Signaling Pathways>> Immunology/Inflammation>> PGE synthase>>SAR191801

SAR191801

Catalog No.GC12330

SAR191801 is a hPGDS inhibitor ,with IC50 of 12 nM in the Fluorescence Polarization Assay or the EIA assay.

Products are for research use only. Not for human use. We do not sell to patients.

SAR191801 Chemical Structure

Cas No.: 1234708-04-3

Size Price Stock Qty
10mM (in 1mL DMSO)
$287.00
In stock
5mg
$215.00
In stock
10mg
$333.00
In stock
50mg
$1,103.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

hPGDS-IN-1 is a hPGDS inhibitor ,with IC50 of 12 nM in the Fluorescence Polarization Assay or the EIA assay.IC50 value: 12 nMTarget: hPGDSThe detailed information please refer to WO2011044307A1 and WO2010080563A2

References:
[1]. Vandeusen, Christopher L, et al. Phenyloxadiazole derivatives as PGD inhibitors and their preparation, pharmaceutical compositions and use in the treatment of allergic and inflammatory disorders. From PCT Int. Appl. (2011), WO 2011044307 A1 20110414.
[2]. Hahn Chang S. Method for treating macular degeneration using syk multikinase inhibitor, an hPGDS inhibitor and a DP antagonist. From PCT Int. Appl. (2010), WO 2010080563 A2 20100715.
[3]. Weiberth Franz J, et al. Demonstration on Pilot-Plant Scale of the Utility of 1,5,7-Triazabicyclo[4.4.0]dec-5-ene (TBD) as a Catalyst in the Efficient Amidation of an Unactivated Methyl Ester. From Organic Process Research & Development (2012), 16(12), 1967-1969.

Reviews

Review for SAR191801

Average Rating: 5 ★★★★★ (Based on Reviews and 26 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for SAR191801

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.